$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000114420416134190 Filed on November 14, 2016

Income Statement

Concept	2016 Q3	2015 Q4	2015 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue		-$3.240M	$313.4K
YoY Change
Gross Profit		-$2.090M	$458.8K
YoY Change			13292.82%
Gross Profit Margin
Selling, General & Admin	$1.470M	$1.870M	$3.756M
YoY Change	-60.86%	8.72%	61.51%
% of Gross Profit			818.58%
Research & Development	$90.00K	$470.0K	$1.090M
YoY Change	-91.75%	-162.67%	18.11%
% of Gross Profit			237.63%
Depreciation & Amortization	$80.00K	$20.00K	$80.00K
YoY Change	0.0%	-88.89%	224.64%
% of Gross Profit			17.44%
Operating Expenses	$1.560M	$5.710M	$4.846M
YoY Change	-67.81%	482.65%	49.18%
Operating Profit		-$7.800M	-$4.387M
YoY Change		695.92%	35.2%
Interest Expense	$1.760M	-$120.0K	$70.00K
YoY Change	2414.29%		46257.62%
% of Operating Profit
Other Income/Expense, Net			$69.35K
YoY Change			-49632.14%
Pretax Income	$204.7K	-$2.590M	-$3.773M
YoY Change	-105.42%	-22.22%	16.27%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$204.7K	-$4.960M	-$4.318M
YoY Change	-104.74%	-14.63%	33.05%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$800.0K	-$26.11M	-$28.80M
COMMON SHARES
Basic Shares Outstanding	39.57M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q3	2015 Q4	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.400M	$3.700M	$7.800M
YoY Change	-43.59%	-56.47%	-31.58%
Cash & Equivalents	$4.400M	$3.716M	$7.839M
Short-Term Investments
Other Short-Term Assets	$0.00	$110.7K	$500.0K
YoY Change	-100.0%		66.67%
Inventory		$0.00	$170.9K
Prepaid Expenses		$193.3K
Receivables			$1.055M
Other Receivables			$0.00
Total Short-Term Assets	$4.600M	$4.295M	$9.542M
YoY Change	-51.79%	-52.73%	-18.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$100.0K	$171.6K	$484.5K
YoY Change	-79.36%	25.51%	142.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$76.34K	$52.65K
YoY Change	279.87%	58.4%	-89.47%
Total Long-Term Assets	$1.700M	$1.948M	$2.858M
YoY Change	-40.52%	-27.25%	-43.96%
TOTAL ASSETS
Total Short-Term Assets	$4.600M	$4.295M	$9.542M
Total Long-Term Assets	$1.700M	$1.948M	$2.858M
Total Assets	$6.300M	$6.243M	$12.40M
YoY Change	-49.19%	-46.93%	-26.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$200.0K	$814.4K	$1.179M
YoY Change	-83.04%	58.75%	194.83%
Accrued Expenses	$600.0K	$463.7K	$934.7K
YoY Change	-35.81%	82.46%	137.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$900.0K	$2.502M	$3.300M
YoY Change	-72.73%	12.98%	120.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$900.0K	$2.502M	$3.300M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$900.0K	$2.500M	$3.298M
YoY Change	-72.71%	10.33%	119.89%
SHAREHOLDERS EQUITY
Retained Earnings		-$50.93M
YoY Change		44.81%
Common Stock		$32.66K
YoY Change		32.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.400M	$3.742M	$9.059M
YoY Change
Total Liabilities & Shareholders Equity	$6.300M	$6.243M	$12.36M
YoY Change	-49.02%	-46.93%	-26.44%

Cashflow Statement

Concept	2016 Q3	2015 Q4	2015 Q3
OPERATING ACTIVITIES
Net Income	$204.7K	-$4.960M	-$4.318M
YoY Change	-104.74%	-14.63%	33.05%
Depreciation, Depletion And Amortization	$80.00K	$20.00K	$80.00K
YoY Change	0.0%	-88.89%	224.64%
Cash From Operating Activities	$630.0K	-$3.950M	-$3.480M
YoY Change	-118.1%	45.22%	16.78%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$20.00K	-$30.00K
YoY Change	-66.67%	-60.0%	-70.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$160.0K
YoY Change
Cash From Investing Activities	-$10.00K	-$180.0K	-$30.00K
YoY Change	-66.67%	260.0%	-70.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.570M	10.00K	-50.00K
YoY Change	-5240.0%	-110.0%	-133.33%
NET CHANGE
Cash From Operating Activities	630.0K	-3.950M	-3.480M
Cash From Investing Activities	-10.00K	-180.0K	-30.00K
Cash From Financing Activities	2.570M	10.00K	-50.00K
Net Change In Cash	3.190M	-4.120M	-3.560M
YoY Change	-189.61%	43.55%	21.5%
FREE CASH FLOW
Cash From Operating Activities	$630.0K	-$3.950M	-$3.480M
Capital Expenditures	-$10.00K	-$20.00K	-$30.00K
Free Cash Flow	$640.0K	-$3.930M	-$3.450M
YoY Change	-118.55%	47.19%	19.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	55000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	275000	USD
CY2016Q3	us-gaap	Other Assets Current OtherAssetsCurrent	0	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	110663	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	171568	USD
CY2015Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	50000	USD
CY2015Q4	atos	Monthly Earnout Payments Percentage Of Gross Revenue MonthlyEarnoutPaymentsPercentageOfGrossRevenue	0.06	pure
CY2015Q4	atos	Maximum Gross Revenue For Monthly Earnout Payments MaximumGrossRevenueForMonthlyEarnoutPayments	10000000	USD
CY2015Q4	atos	Right To Sell Preferred Stock After Fours Years RightToSellPreferredStockAfterFoursYears	4000000	USD
CY2015Q4	us-gaap	Prepaid Insurance PrepaidInsurance	104954	USD
CY2015Q4	us-gaap	Deposit Assets DepositAssets	39218	USD
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	635047	USD
	us-gaap	Selling Expense SellingExpense	0	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10168413	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3845235	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10798727	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3845235	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1720353	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2240869	shares
	us-gaap	Selling Expense SellingExpense	1187777	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1888236	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	403963	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7208508	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5040939	USD
	us-gaap	Operating Expenses OperatingExpenses	10284521	USD
	us-gaap	Operating Expenses OperatingExpenses	5444902	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10284521	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5444902	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1599667	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	116108	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016Q3	us-gaap	Selling Expense SellingExpense	0	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3773309	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	204689	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-4318111	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	204689	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	204689	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3773309	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3845235	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10168413	USD
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2015Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-544802	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-630314	USD
	atos	Stock Issued During Period Common Shares And Warrants StockIssuedDuringPeriodCommonSharesAndWarrants	4695869	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1000662	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-451196	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-27720	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-45242	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9999872	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4018564	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8500718	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7839439	USD
	us-gaap	Interest Paid InterestPaid	3311	USD
	us-gaap	Interest Paid InterestPaid	1304	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	633962	USD
	atos	Stock Issued During Period Value Issued For Commitment Fees StockIssuedDuringPeriodValueIssuedForCommitmentFees	198523	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	650053	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-26470	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-617094	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	62772	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-524288	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	11298	USD
	atos	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	650053	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	168264	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	227387	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	78265	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-72723	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	408081	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9498557	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4695869	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9449342	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5023	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-110749	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	672282	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-661279	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-131176	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	4456	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	26470	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	392711	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-163333	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	74800	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15553	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-220000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	275000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	272344	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4018564	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10272216	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5023	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-66948	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-43801	USD
	us-gaap	Stock Issued1 StockIssued1	198523	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2015Q4	atos	Sale Of Stock Percentage SaleOfStockPercentage	0.81	pure
CY2015Q4	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.19	pure
CY2016Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1630000	USD
CY2015Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1630000	USD
CY2016Q3	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	0	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	114287	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	285855	USD
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	206337	USD
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	79518	USD
CY2015Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	49121	USD
CY2015Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	200000	USD
CY2016Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	113540	USD
CY2015Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	113540	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	341641	USD
	atos	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue	0	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	242975	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1743540	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1943540	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	399978	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.89
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.95
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	28.90
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.81
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M10D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	35751	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	390424	shares
	atos	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue	0	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	240930	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	185245	shares
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	242356	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	414177	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M14D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7D
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	28.95
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	41.1
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6451077	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P2Y1M2D
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	317986	USD
CY2016Q3	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	1762931	USD
CY2015Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3465895	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	816405	shares
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	930456	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	816405	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	930456	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.00
CY2014Q2	atos	Percentage Of Common Stock Outstanding PercentageOfCommonStockOutstanding	0.020	pure
CY2014Q2	atos	Entitled To Receive Worth Of Common Stock EntitledToReceiveWorthOfCommonStock	30.00
CY2016Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	402228	shares
CY2015Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	555345	USD
CY2015Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	93811	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	510179	USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3787967	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.015
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.015
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3787967	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2177151	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2177151	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	356214	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	49215	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>NOTE 1: NATURE OF OPERATIONS</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company’s fiscal year ends on December 31. </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In December 2011, the Company established the National Reference Laboratory for Breast Health, Inc., or NRLBH, as a wholly-owned subsidiary. NRLBH was the Company’s CLIA-certified laboratory which performed the Company’s nipple aspirate fluid, or NAF, cytology test on NAF specimens including those collected with the Company’s Mammary Aspiration Specimen Cytology Test (MASCT) System. The current version of the MASCT System is called the ForeCYTE Breast Aspirator. The NRLBH provides other test services, including pharmacogenomics tests. On December 16, 2015, the Company sold approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 81</font>% of the capital stock of the NRLBH to the NRL Investment Group, LLC, with the Company retaining a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19</font>% ownership through preferred stock. The Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">50,000</font> at the time of the sale and the right to receive, commencing December 2016, monthly earn-out payments equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6</font>% of gross revenue of NRLBH up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000,000</font>, and the right to sell its preferred stock after four years for the greater of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,000,000</font> or fair market value. The Company has elected to recognize any subsequent gain from the earn-out payments as they are determined realizable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As a result of the sale of the laboratory business, the Company is now focusing on development of its pharmaceutical programs.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	42489	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	169576	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	149623	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	149015	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	149015	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	742181	USD
CY2016Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	402228	shares
CY2015Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	87812	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	23470	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	111282	USD
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	237192	shares
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1200000	USD
CY2016Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	206336	USD
CY2016Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	84539	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	290875	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	206338	USD
CY2016Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	438098	USD
CY2016Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	96248	USD
CY2016Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	100701	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	5023	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	257389	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.07
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-2.04
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.72
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-5.91
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0
CY2015Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.30
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.37
CY2016Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	4138177	USD
CY2016Q3	atos	Other Research And Development And General And Administration Expenses OtherResearchAndDevelopmentAndGeneralAndAdministrationExpenses	87315	USD
	atos	Other Research And Development And General And Administration Expenses OtherResearchAndDevelopmentAndGeneralAndAdministrationExpenses	238565	USD
CY2016Q3	atos	Working Capital WorkingCapital	3700000	USD
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	51395	USD
CY2015Q3	atos	Other Research And Development And General And Administration Expenses OtherResearchAndDevelopmentAndGeneralAndAdministrationExpenses	154291	USD
	atos	Other Research And Development And General And Administration Expenses OtherResearchAndDevelopmentAndGeneralAndAdministrationExpenses	469748	USD

Files In Submission

Name	View Source	Status
0001144204-16-134190-index-headers.html	Edgar Link	pending
0001144204-16-134190-index.html	Edgar Link	pending
0001144204-16-134190.txt	Edgar Link	pending
0001144204-16-134190-xbrl.zip	Edgar Link	pending
atos-20160930.xml	Edgar Link	completed
atos-20160930.xsd	Edgar Link	pending
atos-20160930_cal.xml	Edgar Link	unprocessable
atos-20160930_def.xml	Edgar Link	unprocessable
atos-20160930_lab.xml	Edgar Link	unprocessable
atos-20160930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v450738_10q.htm	Edgar Link	pending
v450738_ex10-3.htm	Edgar Link	pending
v450738_ex31-1.htm	Edgar Link	pending
v450738_ex31-2.htm	Edgar Link	pending
v450738_ex32-1.htm	Edgar Link	pending
v450738_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2016 Q3 Form 10-Q Financial Statement

#000114420416134190 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2016 Q3 Form 10-Q Financial Statement

#000114420416134190 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos